Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study.

Blood (2008) 112 (11): 1742.

https://doi.org/10.1182/blood.V112.11.1742.1742

Published: 2008

Journal Articles

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II Study

Blood (2008) 112 (11): 92.

https://doi.org/10.1182/blood.V112.11.92.92

Published: 2008

Journal Articles

Delineation of Canonical and Non-Canonical NF-κB Pathways in Multiple Myeloma: Therapeutic Implications.

Teru Hideshima, MD, PhD, Noopur Raje, MD, Ruben Carrasco, MD, PhD, Hiroshi Ikeda, MD, PhD, Yutaka Okawa, MD, PhD, Tanyel Kiziltepe, PhD, Sonia Valet, MD, Samantha Pozzi, MD, Dharminder Chauhan, PhD, Constantine Mitsiades, MD, PhD, Klaus Podar, MD, PhD, Yu-Tzu Tai, PhD, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD

Blood (2007) 110 (11): 670.

https://doi.org/10.1182/blood.V110.11.670.670

Published: 2007

Journal Articles

Hedgehog Pathway as a Potential Therapeutic Target in Multiple Myeloma.

Simona Blotta, MD, Joeseph Negri, Purushothama Nanjappa, Anne-Sophie Moreau, MD, Rao Prabhala, PhD, Masood Shammas, PhD, Dheeraj Pelluru, PhD, Douglas McMillin, PhD, Yu-Tzu Tai, PhD, Pierfrancesco Tassone, MD, Kenneth C. Anderson, MD, Constantine Mitsiades, MD, PhD, Nikhil C. Munshi, MD

Blood (2007) 110 (11): 672.

https://doi.org/10.1182/blood.V110.11.672.672

Published: 2007

Journal Articles

Lenalidomide and Bortezomib: Targeting Osteoclastogenesis, Osteoclast Survival Factors, and Bone Remodeling Markers in Multiple Myeloma.

Iris Breitkreutz, MD, Marc S. Raab, MD, Sonia Vallet, MD, Teru Hideshima, MD, Noopur Raje, MD, Constantine Mitsiades, MD, PhD, Dharminder Chauhan, PhD, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD

Blood (2007) 110 (11): 1184.

https://doi.org/10.1182/blood.V110.11.1184.1184

Published: 2007

Journal Articles

Akt Inhibitor Perifosine-Induced Cytotoxicity Is Associated with Significant Downregulation of Survivin in Human Multiple Myeloma (MM) Cells.

Teru Hideshima, MD, PhD, Hiroshi Yasui, MD, PhD, Laurence Catley, MD, Noopur Raje, MD, Dharminder Chauhan, PhD, Kenji Ishitsuka, MD, PhD, Klaus Podar, MD, PhD, Constantine Mitsiades, MD, PhD, Yu-Tzu Tai, PhD, Sonia Vallet, MD, Tanyel Kizitepe, PhD, Enrique Ocio, MD, PhD, Hiroshi Ikeda, MD, PhD, Yutaka Okawa, MD, PhD, Hiromasa Hideshima, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD

Blood (2006) 108 (11): 3410.

https://doi.org/10.1182/blood.V108.11.3410.3410

Published: 2006

Journal Articles

Targeting Cyclin D1 in the Treatment of Multiple Myeloma: Preclinical Validation of a Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00.

Noopur Raje, MD, Teru Hideshima, MD,PhD, Sonia Vallet, MD, Shweta Chhetri, Constantine Mitsiades, MD,PhD, Melissa Rooney, Hiroshi Yasui, Tanyel Kiziltepe, Klaus Podar, Yutaka Okawa, Hiroshi Ikeda, Dharminder Chauhan, Nikhil C. Munshi, Somesh Sharma, Himanshu Parikh, Bruce Chabner, Kenneth C. Anderson

Blood (2006) 108 (11): 3454.

https://doi.org/10.1182/blood.V108.11.3454.3454

Published: 2006

Journal Articles

Histone Deacetylase-6 (HDAC6) Modulates Akt and STAT3 Activity Via Heat Shock Protein (Hsp) 90 in Human Multiple Myeloma (MM) Cells.

Teru Hideshima, MD, PhD, James E. Bradner, MD, Hiroshi Yasui, MD, PhD, Noopur Raje, MD, Dharminder Chauhan, PhD, Klaus Podar, MD, PhD, Yu-Tzu Tai, PhD, Constantine Mitsiades, MD, PhD, Paul G. Richardson, MD, Ralph Mazitschek, PhD, Stuart L. Schreiber, PhD, Kenneth C. Anderson, MD

Blood (2006) 108 (11): 3426.

https://doi.org/10.1182/blood.V108.11.3426.3426

Published: 2006

Journal Articles

Perifosine, an Oral Bioactive Novel Alkyl-Phospholipid, Inhibits Akt and Induces In Vitro and In Vivo Cytotoxicity in Human Multiple Myeloma (MM) Cells.

Teru Hideshima, MD, PhD, Laurence Catley, MD, Hiroshi Yasui, MD, PhD, Kenji Ishitsuka, MD, PhD, Noopur Raje, MD, Constantine Mitsiades, MD, PhD, Klaus Podar, MD, PhD, Nikhil C. Munshi, MD, Dharminder Chauhan, PhD, Paul G. Richardson, MD, Kenneth C. Anderson, MD

Blood (2005) 106 (11): 250.

https://doi.org/10.1182/blood.V106.11.250.250

Published: 2005

Journal Articles

Targeting IKK Inhibits Multiple Myeloma (MM) Cell Growth in the Bone Marrow Microenvironment.

Teru Hideshima, MD, PhD, Pierfrancesco Tassone, MD, Dharminder Chauhan, PhD, Kenji Ishitsuka, MD, PhD, Constantine Mitsiades, MD, PhD, Noopur Raje, MD, Shaji Kumar, MD, Makoto Hamasaki, MD, PhD, Hiromasa Hideshima, Nikhil C. Munshi, MD, Paul G. Richardson, MD, David Schenkein, MD, Kenneth C. Anderson, MD

Blood (2004) 104 (11): 2351.

https://doi.org/10.1182/blood.V104.11.2351.2351

Published: 2004

Journal Articles

Molecular Characterization of PS-341 (bortezomib) Resistance: Implications for Overcoming Resistance Using Lysophosphatidic Acid Acyltransferase (LPAAT)-β Inhibitors.

Teru Hideshima, MD, PhD, Dharminder Chauhan, PhD, Kenji Ishitsuka, MD, PhD, Noopur Raje, MD, Shaji Kumar, MD, Klaus Podar, MD, PhD, Constantine Mitsiades, MD, PhD, Hiromasa Hideshima, Lynn Bonham, PhD, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Jack W. Singer, MD, Kenneth C. Anderson, MD

Blood (2004) 104 (11): 2411.

https://doi.org/10.1182/blood.V104.11.2411.2411

Published: 2004

Journal Articles

Increased TCF-4 Expression Correlates with Reduced Caspase-3 Induction and Confers Resistance to Bortezomib.

Reshma Shringarpure, PhD, Deepak Bhole, PhD, Renate Burger, PhD, Laurence Catley, MBBS, FRACP, FRCPA, Klaus Podar, MD, PhD, Yu-Tzu Tai, PhD, Teru Hideshima, MD, PhD, Constantine Mitsiades, MD, PhD, Nikhil C. Munshi, MD, Dharminder Chauhan, PhD, Kenneth C. Anderson, PhD

Blood (2004) 104 (11): 285.

https://doi.org/10.1182/blood.V104.11.285.285

Published: 2004

Journal Articles

Combination of the mTOR Inhibitor Rapamycin and Revlimid™ (CC-5013) Has Synergistic Activity in Multiple Myeloma (MM).

Noopur Raje, MD, Shaji Kumar, MD, Teru Hideshima, MD, PhD, Kenji Ishitsuka, MD, Dharminder Chauhan, PhD, Constantine Mitsiades, MD, PhD, Klaus Podar, PhD, Steven Le Gouill, MD, Paul Richardson, MD, Nikhil C. Munshi, MD, David I. Stirling, PhD, Joseph H. Antin, MD, Kenneth C. Anderson, MD

Blood (2004) 104 (11): 1492.

https://doi.org/10.1182/blood.V104.11.1492.1492

Published: 2004

Journal Articles

P38 MAPK Inhibition Enhances PS-341 (bortezomib)-Induced Cytotoxicity Against Multiple Myeloma Cells.

Teru Hideshima, MD, PhD, Klaus Podar, MD, PhD, Dharminder Chauhan, PhD, Kenji Ishitsuka, MD, PhD, Constantine Mitsiades, MD, PhD, Yu-Tzu Tai, PhD, Makoto Hamasaki, MD, PhD, Noopur Raje, MD, Hiromasa Hideshima, George Schreiner, MD, PhD, Aaron Nguyen, PhD, Tony Navas, PhD, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Linda S. Higgins, PhD, Kenneth C. Anderson, MD

Blood (2004) 104 (11): 3348.

https://doi.org/10.1182/blood.V104.11.3348.3348

Published: 2004

NARROW

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study.

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II Study

Delineation of Canonical and Non-Canonical NF-κB Pathways in Multiple Myeloma: Therapeutic Implications.

Hedgehog Pathway as a Potential Therapeutic Target in Multiple Myeloma.

Lenalidomide and Bortezomib: Targeting Osteoclastogenesis, Osteoclast Survival Factors, and Bone Remodeling Markers in Multiple Myeloma.

Akt Inhibitor Perifosine-Induced Cytotoxicity Is Associated with Significant Downregulation of Survivin in Human Multiple Myeloma (MM) Cells.

Targeting Cyclin D1 in the Treatment of Multiple Myeloma: Preclinical Validation of a Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00.

Histone Deacetylase-6 (HDAC6) Modulates Akt and STAT3 Activity Via Heat Shock Protein (Hsp) 90 in Human Multiple Myeloma (MM) Cells.

Perifosine, an Oral Bioactive Novel Alkyl-Phospholipid, Inhibits Akt and Induces In Vitro and In Vivo Cytotoxicity in Human Multiple Myeloma (MM) Cells.

Targeting IKK Inhibits Multiple Myeloma (MM) Cell Growth in the Bone Marrow Microenvironment.

Molecular Characterization of PS-341 (bortezomib) Resistance: Implications for Overcoming Resistance Using Lysophosphatidic Acid Acyltransferase (LPAAT)-β Inhibitors.

Increased TCF-4 Expression Correlates with Reduced Caspase-3 Induction and Confers Resistance to Bortezomib.

Combination of the mTOR Inhibitor Rapamycin and Revlimid™ (CC-5013) Has Synergistic Activity in Multiple Myeloma (MM).

P38 MAPK Inhibition Enhances PS-341 (bortezomib)-Induced Cytotoxicity Against Multiple Myeloma Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only